E. I. Troyanskii

Bio: E. I. Troyanskii is an academic researcher from Russian Academy of Sciences. The author has contributed to research in topics: Radical & Homolysis. The author has an hindex of 2, co-authored 46 publications receiving 29 citations.

Generation and reactions of 3-carboxy- and 3-carbalkoxypropyl radicals

Abstract: 1. The oxidative decarboxylation of glutaric acid and its monoesters (methyl, ethyl, isopropyl, and benzyl) under the influence of Na2S2O8, in the presence of AgNO3, led to the generation of the ROOC (CH2)2 CH2 radicals, where R = H, CH3, C2H5, i-C3H7 or C6H5CH2. 2. The principal transformation products of these radicals are butyric acid and alkyl butyrates, and also γ-butyrolactone. The yield of the lactone relative to butyric acid and its ester increases as follows in the R series: H > i-C3H7 > C2H5 > CH3 ∼ C6H5CH2.

Oxidative heterocyclization of dithioalkanoic acids

Abstract: Dithioacyloxy radicals RCH2C(S)S' are most likely formed upon the one-electron oxidation of (I), and these radicals add to the sulfur atom of the thiocarbonyl group of (I) with the intermediate formation (after oxidation) of RCH2C(S)SSC(S)CH2R (V). The enhanced C-H acidity of the hydrogens in the ~ position to the C(S)S group in (V) facilitates intramolecular oxidative cyclization to (II). This new reaction is the first example of the formation of 1,2dithiol-3-thiones from dithioalkanoic acids. Tetraalkylhexathiaadamantanes were previously found upon the condensation of dithiocarboxylic acids by the action of ZnCI 2 [4].

Compounds and methods for the treatment or prevention of flavivirus infections

Abstract: A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Vapor–Liquid Equilibria, Excess Enthalpy, and Density of Aqueous γ-Valerolactone Solutions.

Abstract: Thermodynamic measurements were made for the binary mixture of water + γ-valerolactone (GVL) and for pure GVL to facilitate the development of the technology of lignin removal from lignocellulosic biomass (Fang, W.; Sixta, H. Advanced Biorefinery based on the Fractionation of Biomass in γ - Valerolactone and Water. ChemSusChem 2015, 8, 73−76). The density and vapor pressure of pure GVL as a function of temperature were measured and correlated for a wide range of the temperatures and pressures. Isothermal vapor–liquid equilibrium (VLE) data of the binary mixture of water + GVL were measured at 350.2 K with a static total pressure apparatus. Absence of an azeotrope was confirmed by circulation still measurements with diluted GVL solutions. Excess molar enthalpy (hE) of the mixture for the whole range of mole fractions including infinite dilution was measured using a SETARAM C80 calorimeter equipped with a flow mixing cell at 322.6 and 303.2 K. The VLE and hE data were used for the optimization of UNIQUAC an...